Novo Nordisk announced its oral GLP-1 has been approved by the FDA to reduce risk for major adverse cardiovascular events in high-risk adults with type 2 diabetes.Approval of oral semaglutide ...
Key points A 68-year-old woman from rural Ontario arrived at her local emergency department with worsening palpitations. Her medical history included breast cancer treated with surgical resection and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback